Real-world treatment outcomes of amivantamab in pre-approval access (PAA) participants with advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (ex20ins)

T.M. Kim; S-H. Lee; G-C. Chang; J-Y. Shih; M.J. Hochmair; J.K. Sabari; A.I. Spira; C.A. Schioppa; J.B. Rose; M. Chioda; A. Panaccione; P. Mahadevia; B.C. Cho

doi:10.1016/j.annonc.2022.02.044

YUHSpace

BROWSE

0 124

Cited 0 times in

Real-world treatment outcomes of amivantamab in pre-approval access (PAA) participants with advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (ex20ins)

Authors: T.M. Kim ; S-H. Lee ; G-C. Chang ; J-Y. Shih ; M.J. Hochmair ; J.K. Sabari ; A.I. Spira ; C.A. Schioppa ; J.B. Rose ; M. Chioda ; A. Panaccione ; P. Mahadevia ; B.C. Cho